Strakowski S M, Tohen M, Flaum M, Amador X
Biological Psychiatry Program, University of Cincinnati College of Medicine, OH 45267-0559.
Schizophr Res. 1994 Dec;14(1):73-81. doi: 10.1016/0920-9964(94)90011-6.
In a sample of 412 patients with psychotic disorders, the authors examined whether comorbid substance use can be reliably diagnosed, is associated with increased rates of affective symptoms and syndromes and specific psychotic symptoms, and is associated with lowered reliability of the DSM-III-R principal diagnosis. Data from the DSM-IV Field Trial for Schizophrenia and Other Psychotic Disorders was analyzed. In this dataset, substance use was scored on a 4-point ordinal scale and reliability was determined using weighted kappa scores. The associations of significant substance use with affective syndromes and symptoms, and psychotic symptoms were analyzed. Kappa statistics were calculated for principal psychotic disorder diagnoses for patients with and without significant substance use. Weighted kappa scores for substance use ratings ranged from 0.27 to 0.96 (median = 0.85). Syndromal depression was significantly associated with current alcohol use in the entire sample and in the subgroup with schizophrenia alone. Grandiose delusions were also associated with substance use. Significant comorbid substance use was not associated with lowered reliability of diagnosing the principal psychotic disorder. These findings support the hypothesis that comorbid substance abuse can be reliably diagnosed and that alcohol abuse is associated with depressive syndromes in patients with psychotic disorders.
在一个包含412名精神障碍患者的样本中,作者研究了共病物质使用是否能够被可靠诊断,是否与情感症状、综合征以及特定精神症状的发生率增加相关,以及是否与DSM-III-R主要诊断的可靠性降低相关。对来自精神分裂症及其他精神障碍的DSM-IV现场试验的数据进行了分析。在该数据集中,物质使用按4分顺序量表计分,可靠性通过加权kappa分数确定。分析了显著物质使用与情感综合征、症状以及精神症状之间的关联。对有和没有显著物质使用的患者的主要精神障碍诊断计算kappa统计量。物质使用评分的加权kappa分数范围为0.27至0.96(中位数 = 0.85)。在整个样本以及仅患有精神分裂症的亚组中,综合征性抑郁与当前饮酒显著相关。夸大妄想也与物质使用相关。显著的共病物质使用与主要精神障碍诊断的可靠性降低无关。这些发现支持了以下假设:共病物质滥用能够被可靠诊断,并且酒精滥用与精神障碍患者的抑郁综合征相关。